In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Meeting to be held in Denver on March 10 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Docebo (NASDAQ:DCBO – Get Free Report) had its target price lowered by research analysts at Scotiabank from $55.00 to $45.00 ...

Fintel reports that on February 28, 2025, Craig-Hallum initiated coverage of MediWound (NasdaqGM:MDWD) with a Buy ...

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...

At the same time, we are committed to evaluating a range of strategic alternatives to maximize value for our shareholders." ...

We recently compiled a list of the 10 Worst Performing IT Services Stocks to Buy According to Analysts. In this article, we are going to take a look at where TechTarget, Inc.

Fintel reports that on February 20, 2025, Craig-Hallum downgraded their outlook for Axon Enterprise (NasdaqGS:AXON) from Buy ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy ...

ACM Research rocketed more than 20% by afternoon trading on Wednesday following its fourth quarter 2024 financial results ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55 ...